[A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Tumor response rate to gefitinib by previously treated patients with advanced non-small-cell lung cancer was approximately 20%. However, there are few reports about effect of re-treatment with gefitinib. A 40-year-old man was given a diagnosis of adenocarcinoma of lung (c-T2N3M1). Response was not obtained with chemotherapy (paclitaxel + carboplatin, vinorelbine + gencitabin). He developed brain metastasis and received whole brain radiation therapy. He was then given gefitinib. Reduction of the primary tumor, brain metastasis, pulmonary metastasis and liver metastasis was seen. Recurrence of pulmonary metastasis and liver metastasis was discovered 8 months after treatment with gefitinib. Therefore, treatment by gefitinib was stopped. Response was not achieved with chemotherapy (docetaxel and amrubicin). At the request of the patient, retreatment with gefitinib was resumed. Disappearance of brain metastasis was achieved. However, primary tumor, pulmonary metastasis and liver metastasis progressed. We reported a case whose brain metastases disappeared with re-treatment with gefitinib. This report is thought to be useful in terms of information about the acquired resistance of gefitinib. Further investigations are needed to determine the indication of re-treatment with gefitinib.